tiprankstipranks
Atai Life Sciences announces key pipeline, corporate updates
The Fly

Atai Life Sciences announces key pipeline, corporate updates

atai Life Sciences provided key clinical pipeline and corporate updates. Pipeline Updates:RL-007: The first patient was recently dosed in the phase 2b study of RL-007 in patients with CIAS. Initial results from this study are expected in the 2nd half of 2024. GRX-917: The clinical development plan has been updated to now proceed with a phase 2 study in patients. The updated plan is anticipated to generate the robust clinical data needed to best support potential registration. More details on the clinical development plan will be provided upon initiation of the study. The updated plan follows the positive results from the phase 1 single and multiple ascending dose study of GRX-917. In this trial, GRX-917 was well-tolerated. Additionally, GRX-917 had an improved pharmacokinetic profile relative to etifoxine and provided pharmacodynamic evidence of GABA receptor target engagement through qEEG. PCN-101: In January 2023, in conjunction with the phase 2a study results of PCN-101, atai announced it would further evaluate the data and work with its subsidiary Perception Neuroscience to determine next steps for the program. atai will continue to support Perception’s development of PCN-101 through the IV-to-subcutaneous bridging study, which is currently on-track to be completed in the middle of 2023. In parallel, atai continues to work with Perception Neuroscience to explore strategic partnership options. COMP360: On February 28th, COMPASS Pathways announced an acceleration of the Pivotal Trial 1 part of the phase 3 program in treatment-resistant depression, with top line data now expected in the summer 2024.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ATAI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles